MoonLake Soars On Positive 52-week Data Of Sonelokimab In Hidradenitis Suppurativa

Source Summary

MoonLake Immunotherapeutics (MLTX), a clinical-stage biotechnology company, on Monday announced positive 52 week results from the Phase 3 registrational VELA-1 and VELA-2 clinical trials evaluating Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa.